However, not all VWD patients respond to DDAVP and DDAVP administration is contraindicated in patients with type 2B VWD, due to increased risk of thrombocytopenia as their VWF has an increased affinity for platelets (Laan et al., 2025). Here, VWF is linked to von Willebrand disease (hereditary or acquired).